Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma: supplementary tables

Aim: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory

diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR).

Patients & methods: Systematically reviewed multiple databases through 22 July 2021. Analyzed variations

in patient characteristics and their relationship with ORR across trials. Results: Among 17 included trials,

key patient characteristics varied substantially: primary refractory (0–69%), refractory to last line of

therapy (LOT) (12–100%), ≥2 prior LOTs (14–100%), ≥3 prior LOTs (0–64%), IPI ≥3 (23–73%), tumor stage

III/IV (50–90%) and median age (56–74 years). ORRs varied substantially (25–83%), correlating with these

characteristics. Conclusion: Differences in patient characteristics significantly contribute to the variability

in ORR across these trials and should be considered when contextualizing efficacy data.